BioAge Labs expands APJ agonist pipeline with biologic candidates

BioAge Labs (BIOA) announced advances in its apelin receptor agonist programs that strengthen the Company’s pipeline of approaches for obesity and other indications. BioAge has entered into an option agreement with JiKang Therapeutics to potentially in-license a novel APJ agonist nanobody. BioAge has also filed a provisional patent application covering internally developed, novel small molecule APJ agonists. The Company plans to advance APJ agonists designed for both oral and subcutaneous administration in order to serve both segments of the obesity market, with the goal of filing an Investigational New Drug application for an asset from its APJ program in 2026.